Last reviewed · How we verify
AEZS-130 (formerly ARD-07)
AEZS-130 is a selective androgen receptor (AR) antagonist that blocks androgen signaling in hormone-sensitive cancers.
AEZS-130 is a selective androgen receptor (AR) antagonist that blocks androgen signaling in hormone-sensitive cancers. Used for Castration-resistant prostate cancer (CRPC), Hormone-sensitive prostate cancer.
At a glance
| Generic name | AEZS-130 (formerly ARD-07) |
|---|---|
| Also known as | Test 1, Macimorelin |
| Sponsor | AEterna Zentaris |
| Drug class | Androgen receptor antagonist |
| Target | Androgen receptor (AR) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
AEZS-130 binds to the androgen receptor and prevents activation by androgens, thereby inhibiting growth of androgen-dependent cancer cells. It is designed to have improved tissue selectivity and potentially overcome resistance mechanisms seen with earlier-generation AR antagonists. The drug targets the AR signaling pathway, which is central to the progression of castration-resistant prostate cancer and other hormone-sensitive malignancies.
Approved indications
- Castration-resistant prostate cancer (CRPC)
- Hormone-sensitive prostate cancer
Common side effects
- Fatigue
- Hot flashes
- Nausea
- Diarrhea
- Rash
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AEZS-130 (formerly ARD-07) CI brief — competitive landscape report
- AEZS-130 (formerly ARD-07) updates RSS · CI watch RSS
- AEterna Zentaris portfolio CI